Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies
The evaluation of pharmaceutical innovation and therapeutic value is an increasingly complex exercise for which different approaches are adopted at the national level, despite the need for standardisation of processes and harmonisation of public health decisions. The objective of our analysis was to...
Main Authors: | Entela Xoxi, Rossella Di Bidino, Serena Leone, Andrea Aiello, Mariangela Prada |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Medical Technology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmedt.2022.917151/full |
Similar Items
-
How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example
by: Zornitsa Mitkova, et al.
Published: (2023-08-01) -
COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment
by: Beatrice Canali, et al.
Published: (2023-05-01) -
Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-12-01) -
Comparative analysis of the range list of medicines for the treatment of arterial hypertension in accordance with domestic and international clinical guidelines
by: N. V. Sholoiko, et al.
Published: (2022-02-01) -
Access to precision medicine in Thailand: a comparative study
by: Nisita Jirawutkornkul, et al.
Published: (2022-02-01)